Actively Recruiting
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Led by Incyte Corporation · Updated on 2025-12-10
25
Participants Needed
5
Research Sites
250 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
CONDITIONS
Official Title
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Capable of giving signed informed consent including compliance with study requirements
- Currently enrolled and still receiving tafasitamab treatment from a parent study
- Tolerating tafasitamab at the dose specified in the parent study, as assessed by the Investigator
- In complete or partial response, or stable disease, and receiving clinical benefit from tafasitamab as assessed by the Investigator
- Demonstrated compliance with parent protocol requirements
- Willing and able to comply with scheduled visits, treatment plans, and study procedures
You will not qualify if you...
- Legally institutionalized or under judicial protection
- Met criteria for permanent tafasitamab treatment discontinuation per parent protocol
- Able to access tafasitamab outside a clinical study
- Has uncontrolled illness or condition that may jeopardize safety or protocol compliance
- Female who is pregnant, breastfeeding, or a woman of childbearing potential not following contraceptive guidance during treatment and 3 months after last dose
- Male not agreeing to use contraception during treatment and 3 months after last dose if partner is a woman of childbearing potential, or not refraining from donating sperm during this period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Petz Aladar County Teaching Hospital
Győr, Hungary, 09023
Actively Recruiting
2
Hospital S.M. Terni University of Perugia
Terni, Italy, 05100
Completed
3
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
4
Clinica Universitad de Navarra
Pamplona, Spain, 31008
Completed
5
Gazi University Hospital Gazi University Faculty of Medicine
Ankara, Turkey (Türkiye), 06500
Actively Recruiting
Research Team
I
Incyte Corporation Call Center (US)
CONTACT
I
Incyte Corporation Call Center (ex-US)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here